Market Overview

BioMarin to Acquire Rights to Phenylketonuria Franchise From Merck Serono for Upfront Payment of €340M, Plus Milestones


BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that it has acquired all global rights to Kuvan® (sapropterin dihydrochloride) and pegvaliase from Merck Serono (Merck). Under the terms of the agreement, BioMarin will provide Merck with an upfront payment of €340 million. An additional €60 million in milestones will be paid to Merck if combined sales of Kuvan and pegvaliase reach undisclosed cumulative sales thresholds. In addition, €125 million will be paid to Merck for regulatory milestones related to pegvaliase. Previously, BioMarin had exclusive rights to Kuvan in the United States and Canada and to pegvaliase in the United States and Japan. Under the terms of the transaction, BioMarin will now have exclusive worldwide rights to Kuvan and pegvaliase with the exception of Kuvan

See full press release

Posted-In: News M&A Press Releases


Related Articles (BMRN)

View Comments and Join the Discussion!